The nation of Zimbabwe has rejected a major American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' insistence on sensitive data.
The decision became public following a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
A government representative has since clarified that the United States was seeking health data for research and commercial gain while was not willing to share the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more negotiations to find a deal acceptable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This development comes after a comparable case in Kenya, where a high court blocked a related deal with the US after concerns were raised about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
As per statements, 16 nations in Africa have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to surrender its genetic material and health information for a long time, with no equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," he stated.
"Effectively, our country would supply the basic resources for medical research with no assurance that the end products would be accessible to our population if a future disease outbreak emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining structures already set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage further dialogue with our American counterparts on how subsequent collaboration might be structured in a manner that respects the independence and dignity of each country."
Medical Community Reaction
A leading public health body said it recognised the government's concerns, but recommended that talks should continue considering much of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it added.
This impasse highlights the ongoing debate between accepting vital international aid and protecting a country's data in an increasingly data-driven world.